Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis
This study is currently recruiting participants.
Study NCT00004441   Information provided by FDA Office of Orphan Products Development
First Received: October 18, 1999   Last Updated: June 23, 2005   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cystic Fibrosis
Additional conditions recognized in this trial
Fibrosis
More general conditions related to this trial
Digestive System Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Lung Diseases
Pancreatic Diseases
Pathologic Processes
Respiratory Tract Diseases
Interventions listed in this trial
tauroursodeoxycholic acid
ursodiol
Additional drug interventions recognized in this trial
Taurochenodeoxycholic Acid
More general drug interventions related to this trial
Anti-Infective Agents
Antiviral Agents
Cholagogues and Choleretics
Gastrointestinal Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
FDA Office of Orphan Products Development
Children's Hospital Medical Center, Cincinnati


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services